Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells
暂无分享,去创建一个
Michael R. Green | C. Coarfa | K. Bhalla | T. Manshouri | S. Verstovsek | Sunil Sharma | X. Su | T. Kadia | Koichi Takahashi | G. Borthakur | N. Daver | C. Dinardo | S. Kornblau | J. Khoury | N. Pemmaraju | M. Stubbs | C. Vakoc | B. Nabet | L. Masarová | W. Fiskus | C. Mill | G. Montalban-Bravo | P. Bose | C. Birdwell | G. G. Manero | Bernardo H. Lara | D. Perera | Behnam Nabet | Christopher P. Mill | Michael R. Green
[1] D. Bidwell,et al. Formation , 2006, Revue Francophone d'Orthoptie.
[2] P. Cole,et al. Inhibiting the coregulator CoREST impairs Foxp3+ Treg function and promotes antitumor immunity. , 2020, The Journal of clinical investigation.
[3] Michael R. Green,et al. Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors. , 2019, Blood.
[4] Charles C. Bell,et al. Principles and mechanisms of non-genetic resistance in cancer , 2019, British Journal of Cancer.
[5] Guochao Liao,et al. LSD1/KDM1A inhibitors in clinical trials: advances and prospects , 2019, Journal of Hematology & Oncology.
[6] T. Somervaille,et al. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia , 2019, Leukemia.
[7] G. Natsoulis,et al. A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis , 2019, Blood.
[8] M. Kawahara,et al. LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia , 2019, Leukemia.
[9] Mariella G. Filbin,et al. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. , 2019, Cancer cell.
[10] B. A. van der Reijden,et al. Targeting the GFI1/1B—CoREST Complex in Acute Myeloid Leukemia , 2019, Front. Oncol..
[11] E. Wang,et al. What potential is there for LSD1 inhibitors to reach approval for AML? , 2019, Expert opinion on emerging drugs.
[12] G. Schneider,et al. HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β-catenin, MYC, and WT1 , 2019, Cancers.
[13] T. Möröy,et al. Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications , 2019, Front. Oncol..
[14] Michael R. Green,et al. RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1. , 2019, Blood.
[15] Francine E. Garrett-Bakelman,et al. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. , 2019, Cancer discovery.
[16] S. Dawson,et al. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia , 2019, Nature Communications.
[17] Eugene E. Kwan,et al. CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML , 2019, Nature Chemical Biology.
[18] S. Amente,et al. Expanding the Role of the Histone Lysine-Specific Demethylase LSD1 in Cancer , 2019, Cancers.
[19] Y. Inoue,et al. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc. , 2019, Biological & pharmaceutical bulletin.
[20] J. Schütte,et al. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML , 2019, Leukemia.
[21] K. Rajapakshe,et al. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells , 2019, Blood Cancer Journal.
[22] P. Qiu,et al. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML , 2018, Leukemia.
[23] Nghi Nguyen,et al. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth , 2018, Nature.
[24] Karen E Gascoigne,et al. Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. , 2018, Cell reports.
[25] Daniela Magliulo,et al. Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia , 2018, Front. Oncol..
[26] T. Somervaille,et al. LSD1 inhibitors disrupt the GFI1 transcription repressor complex , 2018, Molecular & cellular oncology.
[27] G. Freeman,et al. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade , 2018, Cell.
[28] S. Armstrong,et al. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. , 2018, Blood.
[29] Markus G. Manz,et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.
[30] Yaoyong Li,et al. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia , 2018, Cell reports.
[31] James E. Bradner,et al. The dTAG system for immediate and target-specific protein degradation , 2018, Nature Chemical Biology.
[32] A. Melnick,et al. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. , 2018, Cancer cell.
[33] S. Manalis,et al. Targeting minimal residual disease: a path to cure? , 2018, Nature Reviews Cancer.
[34] Steven P. Angus,et al. Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer. , 2018, Annual review of pharmacology and toxicology.
[35] Yun Song,et al. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors , 2018, Nature Communications.
[36] Darren L. Smith,et al. Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist. , 2017, Cancer discovery.
[37] Sydney M. Shaffer,et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance , 2017, Nature.
[38] R. Sood,et al. Role of RUNX1 in hematological malignancies. , 2017, Blood.
[39] R. Majeti,et al. Biology and relevance of human acute myeloid leukemia stem cells. , 2017, Blood.
[40] R. Young,et al. Transcriptional Addiction in Cancer , 2017, Cell.
[41] P. Qiu,et al. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells , 2016, Leukemia.
[42] Claude Preudhomme,et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.
[43] R. Hara,et al. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells , 2016, Molecular Cancer Therapeutics.
[44] Bradley E. Bernstein,et al. Single-molecule decoding of combinatorially modified nucleosomes , 2016, Science.
[45] F. Robert,et al. GFI1 as a novel prognostic and therapeutic factor for AML/MDS , 2016, Leukemia.
[46] S. Franklin,et al. GFI1 functions in transcriptional control and cell fate determination require SNAG domain methylation to recruit LSD1. , 2016, The Biochemical journal.
[47] Crispin J. Miller,et al. GFI1 proteins orchestrate the emergence of haematopoietic stem cells through recruitment of LSD1 , 2015, Nature Cell Biology.
[48] T. Möröy,et al. From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation. , 2015, Blood.
[49] A. Verma,et al. Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia , 2015, Nature Medicine.
[50] J. Kinney,et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.
[51] Charles Y. Lin,et al. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. , 2015, Molecular cell.
[52] A. Shilatifard,et al. Chromatin signatures of cancer , 2015, Genes & development.
[53] J. Qi,et al. BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD , 2014, Molecular Cancer Therapeutics.
[54] K. Bhalla,et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells , 2014, Leukemia.
[55] J. Qi,et al. Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells , 2014, Molecular Cancer Therapeutics.
[56] Jae-seok Roe,et al. C/EBPα: critical at the origin of leukemic transformation , 2014, The Journal of experimental medicine.
[57] Li Jianguo,et al. Advances and prospects , 2014 .
[58] Mark Cockerill,et al. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1. , 2013, Analytical biochemistry.
[59] S. Amente,et al. The histone LSD1 demethylase in stemness and cancer transcription programs. , 2013, Biochimica et biophysica acta.
[60] Robert A Copeland,et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. , 2013, Blood.
[61] Martin Dugas,et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia , 2012, Nature Medicine.
[62] Z. Otwinowski,et al. Structural basis for CoREST-dependent demethylation of nucleosomes by the human LSD1 histone demethylase. , 2006, Molecular cell.
[63] André Hoelz,et al. Crystal structure and mechanism of human lysine-specific demethylase-1 , 2006, Nature Structural &Molecular Biology.
[64] F. Lan,et al. Regulation of LSD1 histone demethylase activity by its associated factors. , 2005, Molecular cell.